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Description: We aimed to develop an evidence-based guideline for the
non-surgical management of patients with lumbar spine stenosis caus-
ing neurogenic claudication. Using the GRADE approach, the 20-mem-
ber multidisciplinary guidelines panel based recommendations on
evidence from a systematic review of randomized controlled trials and
systematic reviews published through June 2019, or expert consensus if
not trials could be identified. The literature was monitored up to Octo-
ber 2020. Clinical outcomes evaluated included pain, disability, and
walking capacity. This guideline provides updated recommendations
from 2 previous guidelines (North American Spine Society, Danish
Health Authority) based on the best available evidence. Implementing
recommendations issued in this guideline should help clinicians deliver
more consistent care and may help improve patient and healthcare sys-
tem outcomes.
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zzzzAmerican Hip Institute, Des Plaines, IllinoisAbstract: Lumbar spinal stenosis (LSS) causing neurogenic claudication (NC) is increasingly com-
mon with an aging population and can be associated with significant symptoms and functional limi-
tations. We developed this guideline to present the evidence and provide clinical recommendations
on nonsurgical management of patients with LSS causing NC. Using the GRADE approach, a multidis-
ciplinary guidelines panel based recommendations on evidence from a systematic review of random-
ized controlled trials and systematic reviews published through June 2019, or expert consensus. The
literature monitored up to October 2020. Clinical outcomes evaluated included pain, disability, quality
of life, and walking capacity. The target audience for this guideline includes all clinicians, and the tar-
get patient population includes adults with LSS (congenital and/or acquired, lateral recess or central
canal, with or without low back pain, with or without spondylolisthesis) causing NC. The guidelines
panel developed 6 recommendations based on randomized controlled trials and 5 others based on
professional consensus, summarized in 3 overarching recommendations: (Grade: statements are all
conditional/weak recommendations) Recommendation 1. For patients with LSS causing NC, clinicians
and patients may initially select multimodal care nonpharmacological therapies with education,
advice and lifestyle changes, behavioral change techniques in conjunction with home exercise, man-
ual therapy, and/or rehabilitation (moderate-quality evidence), traditional acupuncture on a trial
basis (very low-quality evidence), and postoperative rehabilitation (supervised program of exercises
and/or educational materials encouraging activity) with cognitive-behavioral therapy 12 weeks post-
surgery (low-quality evidence). Recommendation 2. In patients LSS causing NC, clinicians and patients
may consider a trial of serotonin−norepinephrine reuptake inhibitors or tricyclic antidepressants.
(very low-quality evidence). Recommendation 3. For patients LSS causing NC, we recommend against
the use of the following pharmacological therapies: nonsteroidal anti-inflammatory drugs, methylco-
balamin, calcitonin, paracetamol, opioids, muscle relaxants, pregabalin (consensus-based), gabapen-
tin (very low-quality), and epidural steroidal injections (high-quality evidence).
Perspective: This guideline, on the basis of a systematic review of the evidence on the nonsurgical
management of lumbar spine stenosis, provides recommendations developed by a multidisciplinary
expert panel. Safe and effective non-surgical management of lumbar spine stenosis should be on the
basis of a plan of care tailored to the individual and the type of treatment involved, and multimodal
care is recommended in most situations.
© 2021 The Author(s). Published by Elsevier Inc. on behalf of United States Association for the Study of
Pain, Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
Key words: Practice guideline, lumbar spine stenosis, neurogenic claudication, disease management,
nonsurgical treatment, rehabilitation.Background
Spinal pain remains the leading cause of global dis-
ability.17 Lumbar spinal stenosis (LSS), a frequent cause
of chronic low back and leg pain, is associated with sig-
nificant disability and functional limitations. The mean
prevalence estimates for LSS based on clinical or radio-
logical diagnoses vary between 11% and 38% in the
general population (mean age 62, age range 19−93), 15
to 25% in primary care and 29 to 32% in secondary care
populations.61 The prevalence and economic burden
associated with LSS are expected to increase dramati-
cally given the aging population.30,31,123
Lumbar spinal stenosis (LSS) is commonly a degenera-
tive process causing the narrowing of the central spinal
canal, lateral recesses, or intervertebral foramen (or a
combination thereof), progressively compressing the
neurovascular structures in the spinal canal or foramen.
Lumbar spinal stenosis can be classified as acquired
or congenital (developmental) or both and may beassociated with degenerative spondylolisthesis or
scoliosis.10,69,75 Symptomatic LSS is typically described as
neurogenic claudication (NC), characterized by unilat-
eral or bilateral buttock, thigh or calf symptoms (aching,
cramping, pain or sensory/balance problems with pares-
thesia, numbness and weakness) precipitated by pro-
longed standing or walking and relieved by sitting,
lumbar flexion and lying down.64,122 Low back pain
(LBP) may or may not be present with NC.69 These symp-
tomatic individuals report significant limited walking
ability that impacts their capacity to engage in recrea-
tional and social activities, all leading to an important
emotional impact on their lives.4,92,96
Diagnostic decisions require complex judgments that
integrate advanced imaging and clinical findings along
with knowledge of the patient's clinical course.4,30 Clini-
cal classification criteria to identify patients with LSS
causing NC include age over 60 years, positive 30-second
extension test, negative straight leg test, pain in both
ARTICLE IN PRESS
Bussieres et al The Journal of Pain 3legs, and leg pain relieved by sitting, leaning forward or
flexing the spine.44
Although the natural history of mild to moderate
degenerative LSS causing NC tends to be favorable in
approximately 60% of patients (ie, improved or
unchanged back or leg pain),69,85,134 with approximately
30% of patients with LSS expected to worsen,28 this con-
dition remains the most common reason for spinal sur-
gery in patients aged over 65 years.31 While surgery may
rapidly improve pain and disability over nonsurgical
treatments in the first 3 months for some patients with
LSS causing NC,40,78 the clinical benefits may not be sus-
tained beyond 4 to 8 years.58,76. Reoperation rates at 8-
year (18%) 63,78 have been reported. Some studies have
demonstrated a larger proportion of adverse events in
people undergoing surgical (10−24%) versus nonsurgical
(0−3%) care.78,141 Lumbar spinal stenosis surgery is
almost always an elective procedure.75,76 A referral for
special investigations (eg, advanced imaging procedures,
neurological and/or vascular investigations) and/or surgi-
cal consultation is recommended if the patient presents
with severe intermittent claudication (walking ≤ 100
meters), new or progressive lower limb weakness,127 and
failure to respond to an appropriate/intensive course of
nonsurgical care, as determined by the patient‘s quality
of life and expectations.
The clinical management of LSS causing NC is challeng-
ing. The North American Spine Society (NASS) clinical
practice guidelines74 found insufficient evidence to rec-
ommend for or against the use of pharmacological or
nonpharmacological treatments, while the Danish Health
Authority (DHA) guideline105 recommended against
paracetamol, nonsteroidal anti-inflammatory drugs
(NSAIDs), opioids, neurogenic pain medication, muscle
relaxants or manual therapy to treat these patients. The 2
guidelines currently available need to be updated
because their recommendations were informed by evi-
dence published more than 10 (NASS)74 and 4 (DHA)105
years ago respectively. Considering the substantial lack of
high-quality evidence for the effectiveness of the inter-
ventions addressed in these guidelines, new trials are
likely to impact the recommendations. Therefore, an
updated, evidence-based clinical practice guideline is
warranted to inform the nonsurgical management of LSS
causing NC.Methods
Panel Composition
The project lead of the Canadian Chiropractic Guide-
line Initiative (A.B.) appointed 2 co-chairs (J.O. and G.S.)
for the guideline panel and nominated the project exec-
utive committee and the remaining guideline panelists.
J.O. served as the lead methodologist, and G.S. helped
ensure multidisciplinary and geographic representation
of the panel and advised on specific duties of panel
members, time commitment, and decision-making pro-
cess for reaching consensus (development of key ques-
tions and of recommendations). The multidisciplinary
guideline panel included 19 individuals representingchiropractic (K.S., J.M.C., J.A.G., S.P., P.S., J.O.), physio-
therapy (C.M.C., F.A.Z), general physician (G.C), acu-
puncture (S.P., P.S., G.C.), kinesiology (D.H.), orthopedic
surgery (A.Y.) neurosurgery (C.-E.C.), clinical epidemiol-
ogy (C. A., A.-A.M), motor control and learning (S.P.),
health services and clinical research (C.T-L, M.J.S.), meth-
odologists (C.C., A.B., C.T-L.), decision maker (G.S.), and
consumer representative (D.H.) to ensure that stake-
holder and patient values and preferences were consid-
ered. The panel also included R.K.J., a member of the
Danish Health Authority Clinical Guidelines for surgical
and nonsurgical treatment of patients with spinal steno-
sis (DHA). Three observers nonvoting members, an epi-
demiologist with expertise in knowledge translation (C.
C.) and 2 decision makers (B.G, R.M.) monitored the
face-to-face meetings of the guideline panel held in
Toronto (February 2018). To ensure wide representa-
tion, a general physician (G.C.) and a chiropractor (P.S.),
both licensed acupuncturists joined the panel in May
2018. Three panel members (J.C., C.A., M.J.S) reported a
conflict of interest through self-declaration. They were
not involved in the voting where they were potentially
conflicted. Two information specialists (J.B., A.T) con-
tributed to searching, and 5 research assistants (H.Y., L.
V., J.J.W., H.M.S., G.C.) were involved in selecting studies
and assessing quality.Scope and Purpose
We used the best available evidence to develop a clin-
ical practice guidelines document for the nonsurgical
management of patients with LSS causing NC. Specifi-
cally, we developed clinical recommendations based on
systematic reviews using the Grades of Recommenda-
tion, Assessment, Development (GRADE) approach.50
The target population is adults (≥18 years of age) with
LSS (acquired, congenital, lateral or central) leading to
NC with or without associated spondylolisthesis.
Excluded from this guideline are adults presenting with
associated radicular symptoms (ie, leg pain secondary to
lumbosacral nerve root pathology) not relieved by sit-
ting or lumbar flexion.
The target users of this guideline are primarily reha-
bilitation clinicians caring for patients with LSS causing
NC in primary, secondary and tertiary health care set-
tings (eg, physicians, physiotherapists, chiropractors,
occupational therapists, acupuncturists, athletic thera-
pists, massage therapists, nurse practitioners), but also
medical specialists (physiatrists, rheumatologists ortho-
pedic surgeons, neurosurgeons), and decision-makers
involved with the organization and delivery of health
care (eg, third party payers, professional associations,
and regulatory boards). The recommendations in this
guideline aim to: 1) promote restoration of function; 2)
reduce the intensity of symptoms; 3) improve health-
related quality of life; 4) prevent or reduce chronic pain
and disability; 5) promote active participation of
patients in their care; and 6) promote consistent high-
quality care for adults with LSS causing NC.
The guideline was developed by the Canadian Chiro-
practic Guideline Initiative in collaboration with the Bone
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Diagnosis andManagement of Lumbar Spinal Stenosis.Ethics
Because no novel human participant intervention was
required, and secondary analyses were considered, this
guideline is exempt from institutional ethics review
board approval.Systematic Review of the Evidence
We updated the systematic reviews previously con-
ducted for the NASS evidence-based clinical guidelines
for multidisciplinary spine care specific to nonsurgical
interventions,69 and the DHA105 up to June 2019.
Our guideline panel initially developed 11 standard-
ized key questions in a PICO format (ie, population,
intervention, comparator, outcome)49 on December 02,
2017. Due to the paucity of literature, the guideline
panel revisited key questions in February 2018 as fol-
lows. Key question 1 on multimodal rehabilitation inter-
ventions covers lifestyle changes, behavioral change
techniques in conjunction with other rehabilitation
methods, manual therapy, exercise and/or rehabilita-
tion, and ancillary nonpharmacological treatments. To
better reflect usual care, a question on medication was
split into 8 distinct key questions (nonsteroidal anti-
inflammatory drugs (NSAID), adjunctive analgesics
(methylcobalamin, paracetamol, and calcitonin), antide-
pressant agents including serotonin−norepinephrine
reuptake inhibitors (SNRIs) or tricyclic antidepressants
(TCAs), opioid, muscle relaxants, and antiseizure neuro-
pathic medication (pregabalin and gabapentin).Table 1. Topics and Key Questions Addressed by the
1. For patients with lumbar spinal stenosis, should multimodal rehabilitatio
pain, and improve function, quality of life, and return to participation?
2. For patients with lumbar spinal stenosis, should acupuncture versus anot
of life, and return to participation?
3. In patients who underwent spinal fusion with or without decompression
used to decrease pain, and improve function, quality of life, and return t
4. For patients with lumbar spinal stenosis, should nonsteroidal anti-inflam
5. For patients with lumbar spinal stenosis, should adjunctive analgesics (m
decrease pain, and improve function, quality of life, and return to partici
6. For patients with lumbar spinal stenosis, should adjunctive analgesics (ca
improve function, quality of life, and return to participation?
7. For patients with lumbar spinal stenosis, should serotonin−norepinephri
another treatment be used to decrease pain, and improve function, qua
8. For patients with lumbar spinal stenosis, should opioidzversus another tr
life, and return to participation?
9. For patients with lumbar spinal stenosis, should muscle relaxantsz be use
participation?
10. For patients with lumbar spinal stenosis, should anti-seizure neuropath
decrease pain, and improve function, quality of life, and return to parti
11. For patients with lumbar spinal stenosis, should anti-seizure neuropath
decrease pain, and improve function, quality of life, and return to parti
12. In patients who underwent spinal fusion with or without decompressio
used to decrease pain, and improve function, quality of life, and return
**The searches encompassed all key questions. Retrieved citations downloaded in E
then separate in RYYAN according to proposed key questions.Supervised training after surgery (Key question 12) cov-
ers presurgical and postsurgical rehabilitation, and post-
surgical manual therapy. Key questions 2 on
acupuncture, and 10 on Epidural Steroid Injections (ESI)
remained unchanged. See Table 1. Standardized key
questions.
Inclusion Criteria
 Population: Adults (≥18 years of age) with LSS
(acquired, congenital with or without spondylolis-
thesis, lateral or central) causing NC, verified with
relevant spine imaging (anatomical evidence of cen-
tral canal and/or lateral recess stenosis on MRI and/
or CT). Patients’ symptoms included NC character-
ized by radiating leg or buttock pain, numbness,
fatigue or loss of sensation in the lower limbs, bal-
ance disturbances, diminished walking capacity, lim-
ited function and loss of activities of daily living,
and worsening of the symptoms by standing and
walking and relieved by sitting, lumbar flexion or
lying down. 7,75,114. Intervention: Non-surgical
interventions including non-pharmaceutical and
pharmaceutical treatments alone or in combination,
and perisurgical rehabilitation:
 Non-pharmacological interventions included but
were not limited to: self-management (eg, relaxa-
tion, information/discussions on pain and stress
self-management, body awareness exercise, seden-
tary and nutritional lifestyle change interventions,
coping, problem solving, improving self-efficacy),
education/behavioral approaches (eg, cognitiveGuideline Development Group
n interventionsyversus another treatment be used to decrease
her treatment be used to decrease pain, and improve function, quality
, should supervised training after surgeryỻversus another treatment be
o participation?
matory drugs (NSAID)z be used?
ethylcobalamin, paracetamol)z versus another treatment be used to
pation?
lcitonin)z versus another treatment be used to decrease pain, and
ne reuptake inhibitors (SNRIs) or tricyclic antidepressants (TCAs)zversus
lity of life, and return to participation?
eatment be used to decrease pain, and improve function, quality of
d to decrease pain, and improve function, quality of life, and return to
ic medication (pregabalin)z versus another treatment be used to
cipation?
ic medication (gabapentin)zversus another treatment be used to
cipation?
n, should Epidural Steroid Injections (ESI) versus another treatment be
to participation?
ndNote were screened based on the inclusion criteria. Admissible articles were
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home and/or supervised exercise, manual therapy
(eg, spinal manipulation, mobilization, massage
therapy), acupuncture, passive physical modalities
(eg, transcutaneous electrical nerve stimulation
(TENS), laser, ultrasound, diathermy), back braces
or supports (eg, strapping and taping), multimodal
rehabilitation intervention (eg, a combination of
advice/education, lifestyle changes, exercise ther-
apy, manual therapy), and perioperative rehabilita-
tion (eg, pre or post-surgical supervised exercise
programs).
 Pharmacological interventions included but were
not limited to: oral medications such as non-steroi-
dal anti-inflammatory drugs (eg, ibuprofen, cele-
coxib, diclofenac or misoprostol), adjunctive
analgesics (eg, vitamin B12, paracetamol, nasal or
intramuscular calcitonin, topical lidocaine), anti-
depressant agents (eg, SNRIs, TCAs, nortriptyline,
duloxetine, sertraline, trazodone or mirtazapine),
opioids (eg, morphine, OxyContin, trenodal,
codeine), muscle relaxants (eg, cyclobenzaprine),
prostaglandins, neuropathic drugs, anticonvulsant
- neuropathic medications (eg, gabapentin, prega-
balin or lereica), and epidural injections (with or
without steroid or anesthetic, or both).
 Comparison: control (no or delayed treatment, or
sham/placebo eg, light massage, detuned ultra-
sound), usual care or other non-pharmacological or
pharmacological interventions.
 Outcomes: Outcomes were categorized according to
these follow-up periods: immediate (up to one
week), short-term (between 1 week and 3 months),
intermediate (between 3 months and 1 year), and
long-term (1 year or longer): 6 leg/back pain inten-
sity (eg, visual analog scale, numerical rating scale),
walking capacity or performance27,62 (eg, Zurich
Claudication Questionnaire (ZCQ)), disability (eg,
Oswestry, Roland Morris Disability, SF-36, PROMIS
global health and well-being questionnaires), qual-
ity of life (eg, EuroQol 5, SF-36),25,55,62. Secondary
outcomes were risk of falls, the need for pain medi-
cation, and adverse events (Appendix 1).
Study designs: Systematic reviews and meta-analyses;
RCTs with an inception cohort of at least 30 participants
per treatment arm at baseline with the specified condi-
tion, because this sample size is considered the mini-
mum needed for non-normal distributions to
approximate the normal distribution;93 and observa-
tional studies (cohort, case-control), nonrandomized
controlled trials (NRCTs), controlled before-after (CBA),
and before-after (BA) studies.Exclusion Criteria
 Population: Patients with: 1) LSS associated with LBP
or radicular symptoms not relieved by sitting orlumbar flexion (usually due to lateral recess stenosis)
or worsen with flexion and a positive SLR (usually
due to disc herniation); 2) other conditions causing
radiating leg pain such as vascular claudication or
hip arthrosis; or 3) radiological instability of the
spine.
 Intervention/comparison: The surgical manage-
ment of LSS, with the exception of perisurgical
rehabilitation.Search Strategy and Study Selection
To identify articles published since the search per-
formed for the updated NASS guideline69 (1966-July
2010) and DHA105 (July 2016 to December 2017) (see
Appendix A. NASS69 and Appendix B. Danish Health
Authority (DHA)32), an information specialist (J.B.)
updated and adapted the search strategies from July 1,
2010 to December 31, 2017 in MEDLINE, ACP Journal
Club, Cochrane Database of Systematic reviews (DCSR),
Database of Abstracts of Reviews of Effectiveness
(DARE), Cochrane Central Register of Controlled Trials,
EMBASE, CINAHL, and US and International Trials regis-
tries. We used subject headings and key terms related to
LSS, nonsurgical interventions, and rehabilitation
(Appendix 2. MEDLINE search strategy).
Electronic search results were downloaded into End-
note X9 reference manager software (Clarivate
Analytics, Philadelphia, Pennsylvania, USA), and dupli-
cates were removed. Random pairs of reviewers inde-
pendently screened citations and abstracts based on
the eligibility criteria using a standardized screening
sheet. They first double screened 15% of the referen-
ces in order to establish coder reliability. If the
Cohen’s kappa inter-rater reliability for inclusion or
exclusion, as indicated by Cohen’s kappa, was satisfac-
tory (> 0.80), the remaining references were split in
half and screened by either the first or second coder.
If the inter-rater reliability was <0.80 the 2 screeners
went through their conflicts and agreed on the crite-
ria before continuing screening. Any disagreements
were resolved through discussions and by consulting
a third reviewer. If the abstracts did not provide
sufficient information to determine inclusion or exclu-
sion, we reviewed the full-text article, using the same
process.
Our initial search yielded 7621 articles (Fig 1). Of the
162 records screened for eligibility, 2 admissible RCTs by
Kim et al (2016),66 and Monticone et al (2014)87, and 3
systematic reviews (SRs) by Ammendolia et al (2013),6
Enthoven et al (2016),35 and Liu et al (2015),74, with rele-
vant RCTs (Friedly et al (2014),39 Yaksi (2007)140) were
included in our synthesis. Seven additional studies,
including 5 SRs (Podichetty et al (2011)100 van Tulder,
et al (2003),129 Chou et al (2017),24 Kuijpers et al
(2011),70 Staiger et al (2003)117), and 2 RCTs (Rodrigues
et al (2014),104 Waikakul et al (2000)132) were considered
in the narrative synthesis when developing consensus-
based recommendations. The articles included and
Figure 1. PRISMA flow diagram: conservative treatment for lumbar spinal stenosis
Search strategies updated in MEDLINE, ACP Journal Club, Cochrane Database of Systematic reviews (DCSR), Data-
base of Abstracts of Reviews of Effectiveness (DARE), Cochrane Central Register of Controlled Trials, EMBASE,
CINAHL, and US and International Trials registries from 1 July 2010 to 31 December 2017; updated from 1 Jan 2014 to
6 June 2019. The literature was monitored up to October 2020.
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in Appendix 3.
Our updated search on June 6th, 2019 in MEDLINE
and Cochrane Central Register of Controlled Trials
(Appendix 2) yielded 4775 articles’ (Fig 1). Of the 194
records screened for eligibility, 4 scientifically admissible
RCTs by Ammendolia et al (2018), 3 Minetama et al
(2019),86 Oka et al (2018),94 and Schneider et al(2019),108 and RCTs from a systematic review by
Machado et al (2017)79 were also included in the synthe-
sis. Coauthors (C.A., J.O., A.B., C.C., K.S.) involved in
updating a 2013 Cochrane review on LSS6 monitored
the literature for new RCTs (up to June 2020), leading to
the including of an RCT by Qin et al (2020).103 The
articles included and excluded after full-text review
from the updated search are listed in Appendix 4.
Figure 2. Consensus Development Process
Adapted from Hsu CC, Sandford BA. The Delphi Technique: Making Sense of Consensus. J Advanced Nursing
32:1008-15. 2007.
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Eligible studies were critically appraised for quality by
2 independent reviewers reaching consensus, with adju-
dication by a third reviewer if needed, using A Measure-
ment Tool to Assess Systematic Reviews (AMSTAR II),113
Cochrane RoB 2 revised tool for assessing RCTs,119 and
Scottish Intercollegiate Network (SIGN) checklists for
observational studies.115 Studies were deemed to have a
low risk of bias if 2 independent reviewers judged that
selection bias, information bias and confounding likely
did not threaten the internal validity of the study.
(Appendix 5. Tables 1-2). The risk of bias was incorpo-
rated into an evidence profile table of the associated
outcomes for corresponding key question. The GRADE
approach provides a defined framework for critically
appraising the body of evidence for each outcome.48Data Extraction
Data from eligible studies were extracted into a prepi-
loted standardized form. Study authors were contacted
to obtain missing data. The data extraction form
included: author, year, country, study design, study popu-
lation, intervention description and dosage, setting of
intervention, comparison group, primary outcomes: leg
pain, walking ability (distance, time), disability, quality of
life, and secondary outcomes: risk of falls, the need for
pain medication, and adverse events. Pairs of reviewers
independently extracted data and reached consensus
through discussion. A third reviewer was used to resolve
disagreements if consensus could not be reached.Development of Guideline
Recommendations
Grading the Evidence and Developing
Recommendations
We used the Guideline Development Tool (GDT)
(http://www.guidelinedevelopment.org/), and assessed
the quality of the body of evidence for our outcomes of
interest by applying the GRADE methodological
approach.47 (see definitions in Table 2).
The results section provides the PICO questions along
with recommendations, definitions of interventions,
supporting evidence, comments and remarks regarding
LSS. Evidence profiles were used to summarize the evi-
dence 48 (Appendix 6, Tables 1-6). The quality of evi-
dence rating (high, moderate, low or very low) reflects
our confidence in the estimate of the effect to support a
recommendation and considers the strengths and limi-
tations of the body of evidence stemming from risk of
bias, imprecision, inconsistency, indirectness of results,
and publication bias. 48 The evidence profiles serve to
describe the grading of each recommendation and the
outcomes used to address a key question. The outcome
estimates and study used for each key question are
described in Appendix 7. Both of these resources pro-
vided the supporting evidence gathered for each recom-
mendation.
Using the Evidence to Decisions Framework (EtD),109
the panel formally met twice (February 2018, Toronto,
Canada and May 2018, Montreal, Canada) to consider
Table 2. Significance of the Four Levels of Evidence According to Grades of Recommendation,
Assessment, Development, and Evaluation (GRADE)
QUALITY OF EVIDENCE DEFINITION
High () We are very confident that the true effect lies close to the estimate of the effect.
Moderate (O) We are moderately confident of the estimated effect: The true effect is likely to be close to the estimate,
but there is a possibility that it is substantially different.
Low (OO) We have limited confidence of estimated effect: The true effect may be substantially different from the
estimated effect.
Very low (OOO) We have very little confidence in the estimated effect: The true effect is likely to be substantially different
from the estimate.
Adapted from Balshem H, Helfand M, Sch€unemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH. GRADE guidelines: 3.
Rating the quality of evidence. J Clin Epidemiol 64:401-406, 2011.
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to determine the strength of each recommendation,
using informed judgment on the quality of evidence
and effect sizes, resource use, acceptability and feasibil-
ity. To make a recommendation, the panel needed to
express an average judgment with respect to the bal-
ance of desirable (eg, reduced pain and disability, walk-
ability) and undesirable (eg, adverse reactions)
consequences of an intervention; confidence in the val-
ues and preferences for the target population based on
recent qualitative studies;18,77 and resource implications
(costs)98 as outlined in the EtD.8 We defined the
strength rating of a recommendation (strong, weak/
conditional) as the extent to which the desirable conse-
quences of an intervention outweigh its undesirable
consequences. A strong recommendation can be made
when the desirable consequences clearly outweigh the
undesirable consequences. In contrast, a conditional or
weak recommendation is made when the desirable con-
sequences likely outweigh the undesirable
consequences.50,126 If the evidence was not compelling,
the decision to write or not write a recommendation
was based on consensus of the panel.
In absence of scientific evidence from admissible
RCTs, the guideline panel considered available studies
(low quality RCTs, observational studies, systematic
reviews of small RCTs), before producing consensus-
based recommendations. These "good practice" rec-
ommendations are based on professional consensus
among the multidisciplinary members of the working
group. The recommendation may be either for or
against the intervention. These types of recommenda-
tions are weaker than the evidence-based recommen-
dations irrespective of whether these are strong or
weak.
Where available, the panel used randomized clinical
trials (RCTs) only to inform recommendations. For ques-
tions where no RCT could be identified, the panel con-
sidered nonexperimental designs. For PICO questions on
pharmaceutical therapy (nonsteroidal anti-inflammato-
ries, adjunctive analgesics, antidepressant agents,
opioids, muscle relaxants, neuropathic medications and
epidural injections), the panel either: 1) updated the
DHA recommendations105 where new evidence was
available; 2) adopted DHA recommendations105 forwhich no new evidence existed; or 3) made no recom-
mendation. For patients with LSS causing NC with LBP,
the panel relied on indirect evidence from recent
guidelines19,22,88,102 and systematic reviews.33,80,82,106,138
addressing the management of LBP.
The panel provided recommendations based on the
evidence if statistically and clinically significant differen-
ces were found. The panel followed a 2-step process in
making a recommendation. First, in the absence of stan-
dardized cut-off values to determine minimal clinically
important differences (MCIDs) when quantifying treat-
ment effectiveness,133 the panel reached a consensus
decision that a 20% within-group change in the out-
come of interest in any arm of a study was required to
make a recommendation. The decision to use a 20%
within-group threshold was informed by current pub-
lished reports and relevant available MCIDs.15,23,54,118
However, MCIDs can vary across populations, settings,
and conditions and depending on whether within-
group or between-group differences are being assessed.
Therefore, the panel considered MCID values for the
most relevant outcomes.
We reached a consensus decision that the thresh-
olds for MCIDs should reach a between-group differ-
ence following treatment of 10 points on 0- to 100-
point Visual Analogue Scale (VAS), 1 point on 0- to
10-point Numerical Rating Scale (NRS), 2 points on 0-
to 24-point Roland-Morris Disability Questionnaire
(RMDQ), 10 points on 0- to 100-points for Oswestry
Disability Index (ODI), at least 0.52 for the physical
component and 0.48 for symptom variability on the
Zurich Claudication Questionnaire (ZCQ), and a dif-
ference of at least 0.12 on the EuroQol 5 Dimensions
(EQ-5D). Definitions for these outcome measures are
provided in the glossary of terms. Finally, the panel
agreed to a MCID of 30% between-group difference
for walking distance, and a standardized mean dif-
ference (SMD)/effect size of 0.2 to 0.5 between
groups for any outcomes. These thresholds were
informed by the methods in the DHA,105 and the
Agency for Healthcare Research and Quality (AHRQ)
Comparative Effectiveness Review (CER).23
Secondly, the results from relevant studies were used
to formulate a recommendation where appropriate. A
detailed summary of evidence for each key question is
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tive was recommended by our panel when we found
statistically significant between group differences and
clinical significance based on the MCID applied in the
study. If a study found 2 or more treatments together to
be effective compared to a control based on our thresh-
old, then the panel recommended all effective treat-
ments together.
The EtD frameworks were completed and recom-
mendations were drafted over a series of conference
calls with panel members after making judgments
about 4 decision domains: quality of evidence (confi-
dence in estimates of effect); balance of desirable (eg,
reduced pain and disability) and undesirable out-
comes (eg, adverse reactions); confidence about the
values and preferences for the target population; and
resource implications (costs).8,9 A synthesis of our
judgments about the domains determined the direc-
tion (ie, for or against an intervention) and the
strength of recommendations (the extent to which
one can be confident that the desirable consequences
of an intervention outweigh the undesirable conse-
quences and are acceptable and feasible). A specific
format was followed to formulate recommendations
using patient description and the treatment compara-
tor.8 Remarks were added for clarification, if needed.
If the desirable and undesirable consequences were
judged to be evenly balanced and the evidence was
not compelling, the panel decided not to write any
recommendation.
A modified Delphi technique was used at an in-person
meeting to achieve consensus on each recommendation
( HYPERLINK "http:// Fig 2 ).14,56 Using an online tool
(www.polleverywhere.com), panelists voted their level
of agreement with each recommendation (including
quality of evidence and strength of recommendation)
based on the 3-point scale (yes, no, neutral). Before vot-
ing, panelists were encouraged to discuss and provide
feedback on each recommendation in terms of sug-
gested wording edits or general remarks. To achieve
consensus and be included in the final manuscript, each
recommendation had to have at least 80% agreement
with a response rate of at least 75% of eligible panel
members. It was further decided to restrict the Delphi
process to 2 rounds, as the previous guidelines69,105
were already based upon careful reviews of the litera-
ture. All recommendations achieved consensus in the
first round.Peer Review
A 9-member external committee composed of stake-
holders, expert clinicians, and researchers from Canada,
United States, Europe, Asia, and Australasia (Appendix
9) independently reviewed the draft manuscript, recom-
mendations, supporting evidence, applicability and fea-
sibility. The AGREE II instrument (rating scales and
open-ended questions) was used to assess the methodo-
logical quality of the guideline.18
For a list of abbreviations and glossary of terms,
please see Appendix 10.Results
Recommendations on the Nonsurgical
Management of Lumbar Spine Stenosis
Causing Neurogenic Claudication
(GRADE)
Evidence-based and expert consensus recommenda-
tions were developed to improve the conservative man-
agement and health outcomes (pain, disability, quality
of life walking distance) of people with LSS managed in
the primary care setting (Tables 3 and 4). For each PICO
question, we first assessed any relevant RCTs, and other
designs only if no RCTs were available. Thus, recommen-
dations for 6 PICO questions were based primarily on
RCTs (Appendix 6, Tables 1-6), while 5 others based on
expert consensus, supported by systematic reviews or
observational studies or indirect evidence from system-
atic reviews or RCTs where available.Discussion
We developed an evidence-based clinical practice
guideline to help clinicians deliver effective interven-
tions to individuals with LSS causing NC. Our recommen-
dations, based on the best available evidence, expert
opinion, and in consideration of patient values and
preferences, intend to assist clinical decision making
and promote healthcare system efficiency.
Our recommendations state which interventions
should be offered; as well as those that should not be
offered because their effectiveness has not been clearly
established.
For patients with LSS causing NC, our recommenda-
tions are primarily based on low to moderate level evi-
dence or consensus from a multidisciplinary working
group. As such, the true treatment effect may differ
from the estimated effects, therefore the results should
be interpreted with caution.
Summary of Recommendations
Clinicians should work in partnership with patients to
develop a patient-centered care plan that considers the
patient’s values and preferences, discussing with them
effective intervention options, as well as risks and bene-
fits of the care plan, and come up with a shared deci-
sion. We suggest clinicians consider offering a
multimodal rehabilitation intervention consisting of a
combination of education, sedentary and nutrition life-
style modification for patients with limited walking abil-
ity and overweight or obese individuals with related
comorbidities, behavioral change techniques in con-
junction with manual therapy (spinal mobilization,
manipulation, massage) of the thoracic and lumbar
spine, pelvis, and lower extremities, and individually tai-
lored supervised and home exercise program (stretches
and strength training, cycling, and body weight-sup-
ported treadmill walking), a trial of acupuncture or anti-
depressants (SNRIs, TCAs), and, in cases where surgery
was performed, postoperative rehabilitation with CBT.
On the other hand, we cannot recommend the use of
Table 3. Benefits and Comparative Benefits of Nonpharmacological Therapies
KEY QUESTION/INTERVENTION RECOMMENDATION STRENGTH OF RECOMMENDATION QUALITY OF EVIDENCE
PICO 1. For patients with lumbar spinal stenosis, should multimodal rehabilitation interventions versus another treatment be used to decrease pain, and mprove function, quality of life, and return to function?
Multimodal therapy For patients with LSS and neurogenic claudication with or without LBP,
we suggest offering a combination of education and advice, manual
therapy and home-based exercise for improvement in walking capac-
ity and symptoms/physical function in the short and long term.
Conditional/Weak Moderate
(O)
Definition:Multimodal rehabilitation interventions may include sedentary and nutrition lifestyle changes, 71,125 behavioral change techniques in conjun tion with manual therapy, exercise and/or rehabilitation,
and ancillary non-pharmacological treatment.
Included studies:We identified 3 RCTs 3,86,108 in which a comprehensive program, including various combination of self-management strategy, with or ithout cognitive behavioral approach, patient education
and advice to stay active, supervised and home exercises (strengthening, stretching, and conditioning exercises, and stationary cycling), and manual t erapy (thrust and non-thrust manipulation, manual spine
stretching) was compared to home exercises or to medical care plus exercise (Appendix 6, Table 1).
Primary outcomes: Functional disability (ODI), leg pain (NRS), physical performance scale of the Zurich Claudication Questionnaire (ZCQ) or Swiss Spina tenosis (SSS) questionnaire, physical function (SF-36),
and walking distance (Self-Paced Walk Test (SPWT))/gait disturbance (Japanese Orthopaedic Association Back Pain Evaluation Questionnaire).
Key results: In one RCT (Ammendolia 2018) 3, the adjusted mean difference (MD) in walking distance in the comprehensive group vs the self-directed g oup was 304.1 m (95% CI, 77.9 to 530.3) at 3 mo and
421.0 m (95% CI, 181.4 to 660.6) at 6 mo. At 6 mo, 82% of participants in the comprehensive group and 63% in the self-directed group achieved t e MCID, (adjusted RR 1.3; 95% CI, 1.0 to 1.7). Both pri-
mary treatment effects persisted at 12-mo favoring the comprehensive program. At 6-mo, the comprehensive program showed significantly greater provements in the ODI walk scale (-0.8; 95% CI, -1.3 to
-0.4) and at 12-mo in the ZCQ, SF-36 physical function and bodily pain scores.
In one other RCT (Schneider 2019), 108 manual therapy/individualized exercise had greater, but non-clinically important improvement of symptoms/phy cal function (Swiss Spinal Stenosis (SSS) questionnaire) at
2 mo, compared to medical care (adjusted mean difference -2.0; 95% CI: -3.6 to -0.4) or group exercise (-2.4; 95% CI: -4.1 to -0.8). Using the >30% esponder criterion (secondary responder analyses), man-
ual therapy/exercise had a greater proportion of responders in symptoms/physical function (20%; omnibus P = .002) and walking capacity (Self-Pace Walking Test) (65.3%; omnibus P = .04) at 2-mo com-
pared to medical care (7.6% and 48.7%) or group exercise (3% and 46.2%). Group exercise also had greater improvement in average daily physical ctivity (armband accelerometer) at 2 -mo compared to
medical care (28.7; 95% CI: 2.7 to 54.7). At 6-mo, there were no between-group differences in mean outcome scores or responder rates.
In the third RCT (Minetama (2019),86 the supervised physical therapy group showed significant greater improvement at 6 wk vs home exercise in ZCQ mptom severity and physical function (mean difference
(MD) 0.4; 95% CI: 0.6 to 0.2), walking distance on the SPWT (MD 455.9 m; 95% CI: 308.5 to -603.2), leg pain (MD 1.4; 95%CI: 2.5 to 0 ), gait disturbance (MD 16.0; 95%CI: 5.4 to -26.7), and
physical functioning (MD 9.2; 95%CI: 2.1 to -16.3).
Comment: The panel determined a moderate certainty in the evidence, with minor and transitory undesirable effects and no major adverse events repo ted.
Remarks: Multimodal rehabilitation intervention was delivered twice weekly over 6 wk. It included individualized instruction on exercise and self-mana ment strategies using a cognitive behavioral approach.
At the end of the program, daily home exercise (30 min cycling plus 30 min of structured exercises) and self-care strategies should be maintained.3,10
PICO 2. For patients with lumbar spinal stenosis, should acupuncture versus another treatment be used to decrease pain, and improve function, quality f life, and return to function?
Acupuncture For patients with LSS and neurogenic claudication with or without LBP,
we suggest considering traditional acupuncture on a trial basis to
improve pain and physical function in the short-term.
Conditional/Weak Very low
(000)
Definition: Needle acupuncture (eg, Hwato Acupuncture, Suzhou, China; 0.30£40 mm/0.30£75 mm) at various sites (eg, Acupoints of Shenshu (BL23 Dachangshu (BL25), Weizhong (BL40), Chengshan
(BL57), and Taixi (KI3)) 103 or outward from the spinous process bilaterally at L2, L4, S2, and S4, middle of the popliteal fossa, inferior recess in the fib lar head, lower end of the groove of the inner and outer
head of the gastrocnemius).87
Included studies:We identified 2 RCTs 87,103 investigating the effect of acupuncture in patients with NC caused by LSS (Appendix 6 Table 2).
Primary outcomes: Physical function (RMDQ) and physical performance (ZCQ)



































































KEY QUESTION/INTERVENTION RECOMMENDATION STRENGTH OF RECOMMENDATION QUALITY OF EVIDENCE
Key results: A RCT by Qin et al (2020) 103 compared acupuncture to noninsertive sham acupuncture for 24 treatments over 8-wk in patients LSS with N . The acupuncture group showed significant greater
improvement in disability at 8 wk (adjusted mean difference (MD) -2.6 [95% CI, -3.7 to -1.4]) and at 3 mo (MD -2.3 [95% CI, -3.9 to -0.7], but not a 6-mo. The acupuncture group also showed greater
improvement in leg and buttock pain intensity (NRS) at 8 wk (MD -2.9 [95% CI, (-3.8 to -2.0)], 3 mo MD -2.4 [95% CI, -3.3 to -1.4)] and 6 mo (MD - .1 [95% CI, -3.0 to -1.2]), and back pain (NRS) at 8 wk
(MD -2.3 [95% CI, -3.0 to -1.5]) and 3 mo [95% CI -1.7 (-2.6 to -0.8]).
A low-quality comparative study by Oka et al (2018) 87 assigned 119 Japanese patients with LSS and L5 radiculopathy (mixed population) to receive ei er acupuncture (5 sessions in one month), back flexion
exercises and an educational manual or pain medication (acetaminophen). Significant reduction in symptom severity was observed in all 3 groups, w ile improved physical function was found in the acupunc-
ture group only (MD  2.1, 95% CI  0.40 to  0.01). The acupuncture group also demonstrated better physical function compared to exercise gro p at 1 month (between-group difference in ZCQ least-
square mean = 2.17, P = .02).
Comment: The panel determined a moderate certainty in the evidence, with minor and transitory undesirable effects and no major adverse events rep ted. The most frequently reported transient minor
adverse events were worsening of symptoms, general discomfort, pain at the treated areas, and body ache. 57 The resources required for an acupun ure intervention are relatively small (cost of care and
equipment needed), with the exception of training and certification to provide the technique.
Remarks: There is very low quality evidence from 2 small trials that acupuncture provides marginal short-term improvement in pain and functional reco ery for degenerative LSS. Current evidence provides bor-
derline clinically important short-term improvement and is insufficient to suggest long-term benefit.
PICO 3. In patients who underwent spinal fusion with or without decompression, should supervised training after surgery versus another treatment be sed to decrease pain, and improve function, quality of
life, and return to function?
Supervised training after surgery For patients with LSS and neurogenic claudication, we suggest offering
post-operative rehabilitation with CBT to reduce pain and improve
function at 1 month and 12 mo postsurgery.
Conditional/Weak Low
(00)
Definition: Post-operative rehabilitation was defined as a supervised program of exercises and/or educational materials encouraging activity 12 wk afte surgery. Supervised exercise may include active spinal
mobilization, strengthening of spinal deep muscles, stretching of lower limb and low back, functional exercise, walking, and ergonomic advice.
Included studies: A RCT by Monticone et al (2014) 87 compared individual 60-min sessions twice/wk of cognitive-behavioral therapy (CBT) for 4 wk co bined with exercise (90-min session 5 times/wk for 4 wk)
to exercise therapy alone in of patients with post-operatively following lumbar fusion due to LSS with NC (Appendix 6, Table 3).
Outcomes: Functional disability (ODI), back and leg pain intensity (NRS)
Key results: At 1 month, CBT + exercise had significantly less disability (MD: 11.37 (95% CI, 8.68 to 14.07) and back pain (MD: 1.98 (95% CI, 1.62 to 2 4) compared to exercise alone. At 12 mo, CBT + exercise
had significantly less disability (MD: 11.1 (95% CI, 8.72 to 13.81), back pain (MD: 2.77 (95% CI, 2.41 to 3.13), and leg pain (MD: 1.13 (95% CI, 1.0 to 1.65) compared to exercise alone. A small proportion
of participants in both groups reported minor transitory pain worsening and mood alterations.
Comments: The panel determined a low certainty in the evidence, with minor and transitory undesirable effects and no major adverse events reported
SSS, Swiss spinal stenosis questionnaire; ZCQ, Zurich claudication questionnaire; SF-36, Short Form 36; NPRS, The Numeric Pain Rating Scale; RMDQ, Roland Morris Disab ity Questionnaire; ODI, Oswestry Disability Index; CBT, cognitive-
behavioral therapy; MD, mean difference; MCID, minimal clinically important difference; RCT, randomized controlled trial; RR, relative risk.

















































Table 4. Benefits and Comparative Benefits of Pharmacological Therapies
KEY QUESTION/INTERVENTION RECOMMENDATION STRENGTH OF RECOMMENDATION QUALITY OF EVIDENCE
PICO 4. For patients with lumbar spinal stenosis, should nonsteroidal anti-inflammatory drugs (NSAID) be used for patients with lumbar spine stenosis?
NSAIDs For patients with LSS and neurogenic claudication with or without LBP,
we do not suggest the use of NSAIDs for any duration.
Conditional/Weak Low (OO)
Definition: Anti-inflammatory drugs in the form of NSAIDs (eg, naproxen 250−500 mg or ibuprofen 400−600 mg 3−4 times or twice daily) with treatment duration from 4 to 12 wk.
Included studies:We did not identify any RCT investigating the effect of NSAID in patients with NC caused by LSS (Appendix 6, Table 4). Patients with LSS often presents with LBP. The panel considered indirect
evidence from 2 systematic reviews (Enthoven et al (2016), 35 Machado et al (2017) 79) reporting a statistically, but non-clinically significant immediate and short-term benefit favoring NSAIDs compared to
placebo in reducing LBP. NSAIDs increased the risk of gastrointestinal adverse effect.73,74.
Comment: The panel determined a low certainty in the evidence, with small desirable effects (many of the estimates did not meet MCID), and a moderate risk of undesirable effects reported.
Remarks: Consider possible drug interactions and potential differences in gastro-intestinal, liver, cardiovascular and renal toxicity, and the person’s risk factors, including age. 62,139




For patients with LSS and neurogenic claudication with or without LBP,
we do not suggest the use of Methylcobalamin or Paracetamol
(acetaminophen).
Conditional/weak Consensus-based
Definition: Pain medication in the form of oral Methylcobalamin/vitamin B12 (0.5 mg, 3 times/d for 6 mo) or paracetamol (max 4 grams daily for 4-12 wk).
Studies considered: One RCT by Waikakul et al (2000) 132 compared oral Methylcobalamin along with usual care to conventional treatment only (education, activity modification, strengthening exercises for the
trunk and abdominal muscles, physical therapy, and NSAIDs, analgesics and muscle relaxant as needed), and another RCT by Rodrigues et al (2014) 104 compared Paracetamol to either oral corticoid (1 mg/kg/
d with a 1/3 dose reduction weekly) or placebo for 3 wk.
Primary outcomes:Walking distance (Meters), pain (VAS), functional disability (RMDQ and 6-min walk test), quality of life (SF-36).
Key results: No between group difference was observed in those trials.
Comments: The panel determined a very low certainty in the evidence, with uncertain desirable effects and a risk of undesirable effects. The panel decided to pursue consensus-based recommendation.
Remarks: Paracetamol cannot be recommended at this time for neurogenic pain. Further, Paracetamol is unlikely to provide clinical benefit for concurrent acute or chronic LBP. Other treatment options should
be considered in case of persistent and function-limiting symptoms considering potential adverse effects.
PICO 6. Should Adjunctive Analgesics (Calcitonin) be Used for Patients with LSS vs other therapies or placebo?
Adjunctive analgesics (Calcitonin) For patients with LSS and neurogenic claudication with or without LBP,
we do not suggest the use of Calcitonin.
Conditional/Weak Consensus-based
Definition: Pain medication in the form of nasal salmon calcitonin spray or intramuscular calcitonin (variable doses)
Studies considered: A review of four small RCTs by Podichetty (2011) 100 found no significant improvement when comparing calcitonin with placebo for pain (VAS) or walking distance. About 5% of patients
reported minor transient side effects (nausea and flushing).
Primary outcomes: Pain (VAS) and walking distance (Meters).
Comments: Although the panel considered this review, it was eventually excluded from the analysis due to a lack of reported data with unclear pooled estimates. The panel decided to pursue consensus-based
recommendation.
Remarks: Calcitonin releases b-endorphins and can be used as an analgesic agent. The most frequently reported transient minor adverse events were nausea and flushing. Other treatment options should be
considered in case of persistent and function-limiting symptoms.
PICO 7. For patients with lumbar spinal stenosis, should serotonin−norepinephrine reuptake inhibitors (SNRIs) or tricyclic antidepressants (TCAs)z versus another treatment be used to decrease pain, and improve
function, quality of life, and return to function?
SNRIs or TCAs For patients with LSS and neurogenic claudication with or without LBP,
we suggest to consider a trial of serotonin−norepinephrine reuptake
inhibitors (SNRIs) or tricyclic antidepressants (TCAs).
Conditional/Weak Consensus-based
















































KEY QUESTION/INTERVENTION RECOMMENDATION STRENGTH OF RECOMMENDATION QUALITY OF EVIDENCE
Definition: SNRIs and TCA are a class of anti-depressant medication commonly used to treat chronic pain.
Included studies: No RCT investigated the effect of SNRIs or TCAs in patients with NC.
Studies considered: The panel considered indirect evidence on the use of SNRIs and TCAs in chronic LBP and neuropathic pain. 59 , 65,102,117, 128, 130, 136
Comment: The panel pursued a consensus-based recommendation, with moderate risk of adverse events considered. The panel concludes that a trial of SNRI or TCA should be considered in patients with LSS
causing NC with LBP.
Remarks: Consider side effects including, but not limited to, cognitive and physical function, cardiovascular issues and postural instability (eg, falls).
PICO 8. For patients with lumbar spinal stenosis, should opioid versus another treatment be used to decrease pain, and improve function, quality of life, and return to function?
Opioids For patients with LSS and neurogenic claudication with or without LBP,
we do not suggest the use of opioids as first line treatment.
Conditional/Weak Consensus-based
Definition: Opioids (eg, morphine 10 mg 3−4 times/d, oxycodone 5−10 mg twice/d or tramadol 50−100 mg 3−4 times/d in addition to non-opioid pain medication and with a treatment duration from 4 to 12
wk) 105.
Studies included: No eligible RCTs investigated the effect of opioids for the treatment of NC caused by LSS.
Studies considered: The panel considered indirect evidence from opioid therapy guidelines for chronic noncancer pain 19, and consensus-based recommendation from the DHA guideline on managing LSS 105.
Comment: The panel pursued a consensus-based recommendation, with strong risk of adverse events considered. Opioids may only be used for patients who have failed to respond to the aforementioned
treatments and only if the potential benefits outweigh the risks for individual patients and after a discussion of known risks and realistic benefits with patients. 19,37 While the potential benefit of opioids for
neurogenic claudication due LSS is unknown, there is strong evidence for the potential side effects of opioid use 19,102.
Remarks: Should a trial of opioids be considered in selected patients who have persistent, problematic pain despite optimized non-opioid therapy, caution should be used with respect to side effects including,
but not limited to cognition, balance, narcotic habituation, overdose and death 19,102.
PICO 9. For patients with lumbar spinal stenosis, should muscle relaxants be used to decrease pain, and improve function, quality of life, and return to function?
Muscle relaxants For patients with LSS and neurogenic claudication with or without LBP,
we do not suggest the use of muscle relaxants.
Conditional/Weak Consensus-based
Definition: Skeletal muscle relaxants (eg, tizanidin 2−4 mg 3−4 times/d, chlorzoxazone 250 mg 3−4 times/d) for 4−12 wk 105.
Studies included: No RCTs investigated the use of muscle relaxants in patients with NC caused by LSS.
Studies considered: Patients with LSS often presents with LBP. The panel considered indirect evidence from systematic reviews (van Tulder, et al (2003),129 Chou et al (2017),24 and guidelines 102,105 addressing
the management of LBP. For acute LBP, there was moderate to strong evidence that different muscle relaxants performed similarly to each other, and are more effective than placebo for short-term pain relief
for patients. However, evidence was insufficient to determine effects on function. For chronic LBP, there was insufficient evidence with inconsistent results and methodological shortcomings to determine the
effects of muscle relaxants. Adverse events however were significantly more prevalent in the muscle relaxants group (RR = 1.50; 95% CI, 1.14 to 1.98), and especially the central nervous system (RR = 2.04;
95% CI, 1.23 to 3.37).
Comment: The panel pursued a consensus-based recommendation, with known undesirable consequences greater than the uncertain desirable effects of muscle relaxants. For patients with LSS causing NC
with LBP, the panel determined there was a low certainty of evidence, with existing studies focusing on LBP of various etiologies. Muscle relaxants may provide short-term pain relief for acute and subacute
LBP, though adverse events secondary to muscle relaxant use should be considered.
Remarks: Important to differentiate true muscle relaxants vs psychogenic relaxants. Psychogenic relaxants are more commonly prescribed and may help improve sleep. For patients with claudication type pain, it
is important to consider the anti-spasm properties of these agents. Risks of transient adverse events should be considered and patients should be monitored. van Tulder et al (2003),129 Chou et al (2017),24
PICO 10. For patients with lumbar spinal stenosis, should anti-seizure neuropathic medication (pregabalin) versus another treatment be used to decrease pain, and improve function, quality of life, and return to
function?
Pregabalin For patients with LSS and neurogenic claudication with or without LBP,
we do not suggest the use of pregabalin for short-term reduction in
pain and improved function.
Conditional/Weak Consensus-based


































KEY QUESTION/INTERVENTION RECOMMENDATION STRENGTH OF RECOMMENDATION QUALITY OF EVIDENCE
Definition:Medication for neurogenic pain (eg, fixed and flexible doses of Pregabalin between 75 mg/d and 600 mg/d)
Studies considered A non-inferiority RCT by Kim et al (2016) 61 compared limaprost, pregabalin or a combination of limaprost and pregabalin.
Primary outcomes: Functional disability (ODI), leg pain (VAS), walking distance (Meters).
Key results: There was no between-group difference in disability between the pregabalin and limaprost (MD: 3.39 (95% CI, -1.28 to 8.06) at 2 mo. Limaprost did not result in inferior outcomes compared with
treatment with pregabalin or pregabalin+limaprost on the ODI. There were no differences in the improvement of leg pain or walking distance among the 3 groups. All groups reported drug-related adverse
events. Compared with the limaprost group, the pregabalin, and limaprost+pregabalin groups showed a significantly higher incidence of drug related adverse events.
Comment: The panel pursued a consensus-based recommendation, with uncertain desirable effects and a risk of undesirable effects reported.
Remarks: Despite their widespread use, recent systematic reviews, meta-analysis and guidelines advise against the use of anti-seizure neuropathic medication (eg, pregabalin and gabapentin) due to limited evi-
dence and significant risk of adverse effects without any demonstrated benefit 34,102,111.
PICO 11: For patients with lumbar spinal stenosis, should anti-seizure neuropathic medication (gabapentin)z versus another treatment be used to decrease pain, and improve function, quality of life, and return
to function?
Gabapentin For patients with LSS and neurogenic claudication with or without LBP,
we do not suggest the use of gabapentin.
Conditional/Weak Very low
OOO)
Definition:Medication for neurogenic pain (eg, Gabapentin 300 mg 3 times/d, increasing to 900 mg, 3 times/d)
Studies included: One small RCT by Yaksi et al (2007) 140 compared gabapentin to placebo (Appendix 6, Table 5).This trial was identified in 2 systematic reviews (Ammendolia et al 2013, 6 and the Danish
National Guideline by Rousing et al (2019) 105.
Primary outcomes: Leg pain (VAS), walking distance (Meters)
Key results: A statistically significant improvement in leg pain and walking distance in favor of gabapentin at 3 and 4 mo follow-up, but the effect size did not reach clinical significance. Patients in both groups
were treated with therapeutic exercises, lumbosacral corset with steel bracing, and NSAIDs. This trial reported that some participants randomized to the gabapentin group (no data specified) experienced mild
to moderate drowsiness or dizziness, or both.
Comments: The panel determined very low certainty in the evidence. Because of this lack of evidence and moderate risk of side effects the recommendation did not favor gabapentin neurogenic pain medica-
tion.
Remarks: Despite their widespread use, recent systematic reviews, meta-analysis and guidelines advise against the use of anti-seizure neuropathic medication (eg, pregabalin and gabapentin) for managing
patients with associated due to limited evidence and significant risk of adverse effects without any demonstrated benefit 34,45,102,111.
PICO 12. In patients who underwent spinal fusion with or without decompression, should Epidural Steroid Injections (ESI) versus another treatment be used to decrease pain, and improve function, quality of life,
and return to function?
Epidural steroid injections (ESI) For patients with LSS and neurogenic claudication with or without LBP,
we do not suggest the use of epidural steroidal injections for short-
term reduction in pain and improved function.
Conditional/Weak High
()
Definition: Lumbar epidural steroid injections can be performed using 3 approaches: translaminar, caudal, or interlaminar. Injections typically contain a glucocorticoid (eg, triamcinolone (60−120 mg), betame-
thasone (6−12 mg), dexamethasone (8−10 mg), or methylprednisolone (60 to 120 mg) with or without an anesthetic (eg, 1−3 mL of 0.25% to 1% lidocaine) under fluoroscopic guidance 39.
Studies included: One RCT by Friedly et al (2014) 39 compared 2 injections of either epidural steroid injection (glucosteroid plus lidocaine) or lidocaine alone. This trial was identified in a systematic review and
meta-analysis by Liu et al (2015) 74 which included 10 RCTs comprising 1010 patients (mixed population) comparing ESI and local anesthetic (Appendix 6, Table 6).

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Bussieres et al The Journal of Pain 15NSAIDs, analgesics (methylcobalamin, paracetamol, cal-
citonin), opioids as a first-line treatment, muscle relax-
ants, antiseizure neuropathic medication (pregabalin),
or epidural steroidal injections.
All recommendations included in this guideline are
based on very low to high risk of bias RCTs. Further, the
overall quality of evidence ranged from very low to mod-
erate considering other factors suggested by GRADE,
such as imprecision and risks of bias, and thus the
strength of recommendations is weak at this time. None-
theless, given that the natural history of mild to moder-
ate degenerative LSS tends to be favorable for about
two-third of patients,69,85,134 the inconclusive evidence
about the moderate to long-term effectiveness
of surgical interventions for people with LSS causing
NC,5,28,78,105,141 the higher risk of adverse events of surgi-
cal compared to nonsurgical interventions,78,141 and evi-
dence that delaying surgery is not detrimental to surgical
outcome,143 a reasonable trial of multimodal rehabilita-
tion intervention with or without selected medication is
warranted for most symptomatic LSS patients prior to rec-
ommending more invasive interventions.Comparisons With Other CPGs and
Reviews on the Management of LSS
While our findings agreed with the DHA105 and
NASS68,69 guidelines regarding the common medica-
tions assessed, divergence in opinion with these 2
guidelines68,69,105 can largely be explained by the use of
different eligibility criteria, and the inclusion of recently
published evidence on multimodal rehabilitation
intervention3,86,108 and acupuncture103 upon which we
were able to base our recommendations.
First, this guideline included a wider population of
adults (≥18 years of age), is restricted to neurogenic
claudication, and applies to a specific audience. Neuro-
genic claudication is due to neuroischemia where the
radicular type is due to nerve root inflammation. The
differing pathophysiology may require different treat-
ment approaches. Further, only RCTs with an inception
cohort of at least 30 participants per arm at baseline
were admissible for non-normal distributions to approx-
imate the normal distribution.93 Importantly, three
recent high to moderate quality RCTs3,86,108 investigated
the effectiveness of various combination of multimodal
rehabilitation that have informed our guideline recom-
mendations, but were not available when the NASS68,69
and DHA105 guidelines were developed.
Second, the NASS guideline68,69 recommended a lim-
ited course of active physical therapy (education and
exercise), while the DHA105 recommended tailored
supervised exercise as an option for patients with LSS .
This guideline suggests clinicians consider offering a
stepped-wise treatment approach with multimodal
rehabilitation as first line treatment (and possibly acu-
puncture), alone or in combination with selected medi-
cation after considering potential risks and patient
preference and values. Interestingly, the proposed
sequential treatment approach parallels
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agement of adults with low back pain.38,102 Using the
GRADE approach, the panel determined that the bal-
ance of desirable and undesirable outcomes favored
multimodal rehabilitation consisting of manual therapy
(spinal mobilization, manipulation, massage) of the tho-
racic and lumbar spine, pelvis, and lower extremities,
and individually tailored supervised and home exercise
program (stretches and strength training, cycling, and
body weight-supported treadmill walking) combined
with cognitive-behavioral therapy. All patients in
Ammendolia (2018)3 and Minetama (2019)86 RCTs were
allowed to continue with previously prescribed medica-
tions, while those in the trial by Schnieder (2019)108
were randomly allocated to usual medical care, group
exercise or manual therapy/individualized exercise.
Results favored “intense” rehabilitation programs of
care. A detailed description of the multimodal rehabili-
tation program is available elsewhere.2
Third, the NASS guideline68,69 found insufficient evi-
dence to support the use of acupuncture while the DHA
guideline105 did not assess this modality. While this
guideline suggest acupuncture may be recommended if
patients have a preference for or willingness to receive
acupuncture, this is based on very low quality evidence
from small RCTs showing borderline clinically important
short-term improvement and is insufficient to suggest
long-term benefit. Whether the results from the trials
conducted in Asia would generalize to another or larger
LSS population remains to be determined.2
Lastly, this guideline recommend against the use of
NSAIDs, methylcobalamin, paracetamol, calcitonin,
opioids, muscle relaxants, pregabalin, or gabapentin. As
patients with LSS often present with LBP, clinicians may
want to considered a review of systematic reviews by
Wong et al (2016)137 concluding that oral NSAIDs are
more effective than placebo for nonspecific chronic LBP,
but not for acute LBP. Guidelines generally advise pre-
scribing oral NSAIDs at the lowest effective dose for the
shortest time possible. Any potential benefits should be
weighed against the risk of harm.80 A Cochrane review
by Saragiotto et al (2016)106 concluded that Paracetamol
does not produce better outcomes than placebo for
people with acute LBP, and it is uncertain if it has any
effect on chronic LBP.
Based on consensus, this guideline and the DHA
guideline105 suggest that opioids should only be used
for patients with LSS who have failed to respond to the
aforementioned treatments, and only if the potential
benefits outweigh the risks for individual patients.
Shared decision making should include a discussion of
known risks and realistic benefits with these
patients.19,33,75,82 The American College of Physician
(ACP) guidelines for LBP including radiculopathy recom-
mended against the use of opioids as a first or second
line treatment.102 Based on indirect evidence,24,129 we
recommend against the routine use of skeletal muscle
relaxants in patients with LSS considering the risks of
transient adverse effects. The DHA105 state in their
guideline "It is good practice to avoid use of muscle
relaxants in these patients, since the beneficial effect isuncertain and there is a risk of adverse reactions, includ-
ing dizziness, fatigue, dry mouth, muscle weakness and
gastrointestinal effects, may outweigh the unknown
potential benefit of muscle relaxants." The ACP guide-
line102 recommended skeletal muscle relaxants as a sec-
ond line treatment for acute and subacute LBP if
pharmacologic therapy is desired.
We also recommended against the use of epidural ste-
roid injections (ESI) for patients with LSS and NC. While
ESI was not covered in DHA guideline,105 the NASS 68,69
guideline recommended interlaminar ESI for short-term
(2 weeks to 6 months) symptom relief in patients with
NC or radiculopathy. There is, however, conflicting evi-
dence concerning long-term (21−24 months) effective-
ness. The difference between our recommendation for
ESI and the NASS guideline68,69 can be explained by the
fact that the NASS inclusion criteria allowed for inclu-
sion of studies of patients with lumbosacral radicular
pain, in addition to those with LSS and NC.72 In contrast,
our inclusion criteria required that patients in the study
were diagnosed specifically with LSS and NC.Function and Participation
Symptomatic LSS strongly impacts individuals’ emo-
tional state, quality of life, and physical function includ-
ing walking, recreational activities such as sports and
exercise, standing, social activities, household activities,
managing comorbid health conditions, working, sleep-
ing and lifting.4,77,96 Thus, health care providers should
be prepared to address negative emotional responses to
LSS and related misconceptions, and provide advice and
education about LSS, including individualized care
based on self-management techniques and lifestyle
changes.77 Sedentary and nutrition lifestyle modifica-
tion for patients with limited walking ability and over-
weight or obese individuals with related comorbidities
may include low-cost wearable accelerometer or
pedometer-based physical activity promotion, nutrition
education by a dietician, and advice from an exercise
physiologist over a 12-week intervention.71,120,125 In a
pilot trial, participants logged on to the e-health Web
site to access personal step goals, nutrition education
videos, and a discussion board.125
Despite the benefits of physical activity for reducing
the risk of chronic health conditions, only 32% of clini-
cians advise older adult patients to begin or continue to
do exercise or physical activity during office visits. 12
Clinicians’ reluctance to prescribe physical activity to
older patients may be attributable to a lack of knowl-
edge regarding appropriate exercise prescription for
older adults in light of the potential risks and benefits
of various doses and types of exercise.142 Barriers to
exercise participation among older adults include fear
of pain or exacerbation of existing pain, low self-effi-
cacy, fear of injury, lack of social support, and social
isolation.29,142 Perhaps as a result, patients with chronic
musculoskeletal pain prefer individually tailored infor-
mation and support when prescribed physical activity. 63
Interventions that combine both behavioral and cogni-
tive behavior change techniques are more effective
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Frameworks and guidelines for exercise prescription in
older adults and modification of these guidelines for
patients with the most common age-associated comor-
bidities are available to assist clinicians.11,142 Pre-exer-
cise screening prior to initiating an exercise program is
recommended, along with considerations to modify
medications if necessary.Dissemination and Implementation Plan
While the potential resource implications (specialized
staff, cost) of applying the guideline recommendations are
considered small, a recent manual by the National Institute
for Health and Care Excellence (NICE) can be used to assess
the financial change in the use of resources (cost or saving)
as a result of implementing this guideline.89
Once a decision to disseminate and/or implement this
guideline has been made to help improve the manage-
ment of patients with LSS leading to NC, the following 6
steps of the Knowledge-to-Action framework may be
considered: 46
Adapting knowledge to local context: Clinicians, insur-
ers and policymakers should consider using the ADAPTE
framework to adapt this guideline to their needs and juris-
dictions.26 Resource-constrained settings may prefer using
alternative approaches described elsewhere.83
Assessing barriers/enablers to knowledge use: Uptake
of guideline recommendations in clinical practice can
be impeded by a wide range of professional (eg lack of
time, knowledge, skills, self-capacity, misperceptions
about evidence-based CPGs,)20,51,116 and organiza-
tional/environmental barriers (eg leadership, organiza-
tional culture, years involved in quality improvement,
data infrastructure/information systems, and resour-
ces).52 Stakeholders and researchers may use the
recently developed Clinician Guideline Determinants
Questionnaire, a validated tool that addresses multiple
potential determinants specific to guideline use from a
clinician perspective.41
Selecting, tailoring, implementing interventions:
Knowledge Translation (KT) strategies to increase the
likelihood of successful guideline uptake and reduce
knowledge-practice gaps should aim to target problem
behaviors of care providers,1,13,95,110 patients,43,107 and
wider health care organizations.53 Numerous theories,
models, and frameworks can be used to inform each step
of the KT process (planning/design, dissemination and
implementation, evaluation, and sustainability) or across
the full KT spectrum (from planning to sustainabil-
ity).91,121 The Expert Recommendations for Implementing
Change (ERIC) taxonomy propose a systematic approach
to specifying active components of implementation strat-
egies when planning small- and large-scale implementa-
tion efforts.99,101 Depending on the specific barriers to
uptake and available resources, interventions can range
from low cost manually-generated reminders delivered
to providers on paper,97 audit and feedback,60and use of
local opinion leaders. 37 Ongoing and frequent theory-
based implementation interventions are recommended
to effectively change clinical practice and improvepatient health.84,26 As with prior guidelines,21,22 we con-
sidered the Guideline Implementation Planning Checklist
42 and available strategies and supporting evidence to
increase guideline uptake.36 To raise awareness, profes-
sional organizations are encouraged to inform their
members of this new guideline and companion docu-
ments for practitioners (Appendix 11) and patients
(Appendix 12) easily accessible at: https://www.ccgi-
research.com/ and http://boneandjointcanada.com/ to
help with “front line” dissemination.
Monitoring the use of the guideline, 5) evaluating its
impact, and 6) assessing sustained use: These steps may
be done through surveys, chart reviews or electronic
health records, and intervention studies to evaluate
impact.60 For instance, the Clinician Guideline Determi-
nants Questionnaire41 can be used at multiple time
points to assess determinants of the use of our new
guideline, before and after implementation of an inter-
vention to demonstrate impact on guideline use or fol-
lowing audit showing failure to routinely apply
guideline recommendations to plan interventions to
sustain guideline use. Identifying indicators of success
should be defined a priori (eg, outcomes related to clini-
cian learning and performance, patient outcomes and
cost-effectiveness of care).Research Implications
Future research should aim to identify and validate
LSS clinical phenotypes (NC pain symptoms; NC claudica-
tion sensory /balance symptoms; NC radicular unilateral
leg pain) and associated severity of symptoms/disability
(ie, mild, moderate, severe) in relationship to the sever-
ity of structural anatomical changes that may more
likely be predictive of those patients who may to benefit
from conservative versus surgical treatment approaches.
Research should also prioritize high quality RCTs testing
various combinations of modalities of nonpharmacolog-
ical (eg, education about self-care, home vs supervised
exercise, manual therapy, acupuncture, CBT and other
psychological interventions, perioperative rehabilita-
tion) and pharmacological treatments (eg, serotonin
−norepinephrine reuptake inhibitors, tricyclic antide-
pressants) and dosage (duration and intensities)
required for optimal benefits for each phenotype, while
considering patient preference,4,16,67,77 and determin-
ing the most important (objective) outcomes that are
meaningful to patients to gauge treatment success
aligned with patients’ goals (eg, participating in recrea-
tional and social activities).81 The completion of RCTs
comparing best medical management with or without
antidepressants (SNRIs or TCAs) in patients with symp-
tomatic LSS is also encouraged. Ongoing trials may pro-
vide partial answers.7,124,135Guidelines Update
Methods for updating these guidelines are as
reported in our prior guidelines21 and others.90,114 The
Canadian Chiropractic Guideline Initiative will follow
the following process: (1) monitoring changes in
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of outcomes, resources available, and relevance of the
recommendations to clinicians (limited systematic litera-
ture searches each year for 3-5 years and survey to
experts in the field annually); (2) assessing the need to
full or partial update (relevance of the new evidence or
other changes, type and scope of the update); and (3)
communicating the process, resources, and timeline to
the Guideline Advisory Committee of the CCGI, who will
submit a recommendation to the Guideline Steering
Committee to make a decision to update and schedule
the process. Further, a recently developed checklist
(CheckUp) will be used to improve the reporting of the
updated guideline.131Strengths and Limitations
This clinical practice guideline was based on compre-
hensive literature search and updated the evidence
from 2 previous guidelines. We used the GRADE
approach providing clear link between recommenda-
tions and evidence. This guideline was peer-reviewed by
international experts who provided detailed comments
prior to release of the final report. Nonetheless, our
guideline also has limitations. First, given that we were
also interested in pharmacological interventions, we
may have missed studies published in Embase related to
the effectiveness of pharmacological therapies in indi-
viduals with LSS causing NC. Second, we only searched
for articles published in English. Third, only 2 databases
(MEDLINE and Cochrane Central) were searched in our
updated search (January 2014 through June 2019). How-
ever, the 3-year search overlap (2014-2017) between the
initial and updated search did not uncover any new
admissible articles, and 4 coauthors (CA, JO, KS, AB)
involved in a parallel Cochrane review using several
additional databases identified only 2 additional admis-
sible RCT86,103 which were incorporated in this guide-
line. Forth, although the composition of the guideline
panel was diverse, with experienced methodologists,
expert clinicians and surgeons, stakeholder and patient
representatives, a majority of the panel members had
clinical training in chiropractic. When updating this
guideline, the future panel should include a larger pro-
portion of GPs, rheumatologists, physiatrists, experts in
pain and interventional radiology, physiotherapists,
occupational therapists, massage therapists, and natur-
opaths. Expanding the multidisciplinary nature of a
future panel will ensure a broader forum for discussion
among panelists. Additional efforts should be made to
include participants from South America, Asia and
Africa. Fifth, patient experiences or expectations were
mainly informed by recent qualitative studies.16,77;
Sixth, the scope of this guideline focused on selected
outcomes such as pain, disability and function although
included studies assessed additional patient outcomes.
In addition, poor descriptions of the interventions eval-
uated by included studies were common; Seventh, our
recommendations were limited by the amount and
quality of evidence published in the literature. The low
quality of evidence mainly related to the randomizationprocess, and deviations from the intended interventions
in RCTs; blinding, incomplete outcome data, and selec-
tive outcome reporting in observational studies. There-
fore, new high-quality trials are likely to impact the
recommendations in future guidelines.8 Given the lim-
ited number of RCTs addressing LSS patients matching
our inclusion criteria, studies did not always explicitly fit
our inclusion criteria. Any differences in LSS patient
population were accounted for in both the wording of
the recommendation/remarks, and the full description
of the evidence precluding to support the recommenda-
tion/remark statement.Guideline Disclaimer
The evidence-based practice guidelines published by
the Canadian Chiropractic Guideline Initiative (CCGI) in
collaboration with Bone and Joint Canada include rec-
ommendations intended to optimize patient care that
are informed by a systematic review of evidence and an
assessment of the benefits and harms of alternative care
options. Guidelines are intended to inform clinical deci-
sion making, are not prescriptive in nature, and do not
replace professional care or advice, which always should
be sought for any specific condition. Furthermore,
guidelines may not be complete or accurate because
new studies that have been published too late in the
process of guideline development or after publication
are not incorporated into any particular guideline
before it is disseminated. CCGI and its working group
members, executive committee, and stakeholders (the
“CCGI Parties”) disclaim all liability for the accuracy or
completeness of a guideline and disclaim all warranties,
expressed or implied. Guideline users are urged to seek
out newer information that might impact the diagnostic
and/or treatment recommendations contained within a
guideline. The CCGI Parties further disclaim all liability
for any damages whatsoever (including, without limita-
tion, direct, indirect, incidental, punitive, or consequen-
tial damages) arising out of the use, inability to use, or
the results of use of a guideline, any references used in
a guideline, or the materials, information, or procedures
contained in a guideline, based on any legal theory
whatsoever and whether or not there was advice of the
possibility of such damages.
Through a comprehensive and systematic literature
review, CCGI evidence-based clinical practice guidelines
incorporate data from the existing peer-reviewed litera-
ture. This literature meets the pre specified inclusion cri-
teria for the clinical research question, which CCGI
considers, at the time of publication, to be the best evi-
dence available for general clinical information pur-
poses. This evidence is of varying quality from original
studies of varying methodological rigor. CCGI recom-
mends that performance measures for quality improve-
ment, performance-based reimbursement, and public
reporting purposes should be based on rigorously devel-
oped guideline recommendations.
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